bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure 1. from VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells
Authors: Tiper Irina V. , Temkin Sarah M. , Spiegel Sarah , Goldblum Simeon E. , Giuntoli Robert L. , Oelke Mathias , Schneck Jonathan P. , Webb Tonya J.
Published: April 2023

Ovarian cancer associated ascites contains soluble inhibitory factors. The ascites was cleared of cellular debris by centrifugation as previously described (18). (A, B) The ascites was filtered 0.2 micron filter and fractionated- f1: <5KDa; f2: 5-50KDa; f3: >50. (C) The ascites was treated with 50 μg/ml proteinase K at 37{degree sign}C for 1 hour and then incubated at 95{degree sign}C for 10min to heat inactivate the enzyme. The antigen presenting cells were treated with the clarified supernantants for 4 h at 37{degree sign}C, then washed extensively with PBS, and cocultured with NKT hybridomas for 20-24 h at 37{degree sign}C. Cytokine released (IL-2) was measured as an indication of NKT cell activation and was measured by standard sandwich ELISA.
Supplementary Figure S5 from The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
Authors: Krepler Clemens , Chunduru Srinivas K. , Halloran Molly B. , He Xu , Xiao Min , Vultur Adina , Villanueva Jessie , Mitsuuchi Yasuhiro , Neiman Eric M. , Benetatos Christopher , Nathanson Katherine L. , Amaravadi Ravi K. , Pehamberger Hubert , McKinlay Mark , Herlyn Meenhard
Published: April 2023

PDF file - 89 KB, TNF-� as a single agent has no effect on cell line proliferation.
Supplementary Table 2 from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
Authors: Gros Alena , Turcotte Simon , Wunderlich John R. , Ahmadzadeh Mojgan , Dudley Mark E. , Rosenberg Steven A.
Published: April 2023

PDF file, 51K, Tumor-derived myeloid subsets from (n=6) were stained and sorted and their suppressive activity was tested in a co-culture with autologous T cells activated with anti-CD3/anti-CD28 beads in duplicates. T cell proliferation was assessed by quantifying the percent of T cells that had not diluted the CFSE at day 4 and calculating the percent inhibition of T cell proliferation. Average percent inhibition � SEM are shown. Average of the cumulative data from the 6 tumorsis also shown.
Supplementary Figure S3 from The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
Authors: Krepler Clemens , Chunduru Srinivas K. , Halloran Molly B. , He Xu , Xiao Min , Vultur Adina , Villanueva Jessie , Mitsuuchi Yasuhiro , Neiman Eric M. , Benetatos Christopher , Nathanson Katherine L. , Amaravadi Ravi K. , Pehamberger Hubert , McKinlay Mark , Herlyn Meenhard
Published: April 2023

PDF file - 110 KB, Immunoblot showing a cohort of birinapant in combination with TNF- � resistant cell lines.
Supplementary Figure Legend from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
Authors: Gros Alena , Turcotte Simon , Wunderlich John R. , Ahmadzadeh Mojgan , Dudley Mark E. , Rosenberg Steven A.
Published: April 2023

PDF file, 42K.
Supplementary Figure 1 from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
Authors: Gros Alena , Turcotte Simon , Wunderlich John R. , Ahmadzadeh Mojgan , Dudley Mark E. , Rosenberg Steven A.
Published: April 2023

PDF file, 50K, The relative frequency of leucocytes in melanoma metastasis (n=14) was determined and represented as a percent of all the live cells in the tumor (left panel) and absolute counts/g of tumor (right panel). 'Others' includes tumor cells, fibroblasts and other cell types that were not separately studied.
Supplementary Figure 5 from PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate–Sensitive or –Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo
Authors: Dasmahapatra Girija , Patel Hiral , Nguyen Tri , Attkisson Elisa , Grant Steven
Published: April 2023

PDF file - 290K, Co-treatment with BI2536 and vorinostat induces regression in flank tumors (K562 cells) and increases the survival of mice with systemic tumors. Tumor size was monitored at the end of (A) 14 days of drug (BI2536 + vorinostat) treatment (B) after stopping treatment for 14 days (C) Tumor progression was monitored using an IVIS bioimager in mice bearing systemic tumor ( BV173/E255K) at the end of the BI2536 + vorinostat (24 day) treatment.
Supplementary Figure 2 from PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate–Sensitive or –Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo
Authors: Dasmahapatra Girija , Patel Hiral , Nguyen Tri , Attkisson Elisa , Grant Steven
Published: April 2023

PDF file - 90K, Various PLK1 and HDAC inhibitors interact synergistically in CML models including those sensitive or resistant to IM. A. LAMA84 cells were treated with BI2536 (2.0 nM) � vorinostat (1.0 �M) for 48 hr. B. K562 cells were treated with BI6277 (7.5 nM) or GW843682(7.5�M) � vorinostat (1.0 �M) or SBHA (30�M) for 48 hr, C. Fractional Effect (FA) values were determined by comparing results obtained for untreated controls and treated cells following exposure to agents administered at a fixed ratio (GW843682: vor = 5:1), after which Median Dose Effect analysis was employed to characterize the nature of the interaction. D. Adult-T315I cells were treated with BI2536 (3.0 nM) � vorinostat (1.0 �M) for 48 hr. Inset: Fractional Effect (FA) values were determined by comparing results obtained for untreated controls and treated cells following exposure to agents administered at a fixed ratio (BI25362: vor = 1:3), after which Median Dose Effect analysis was employed to characterize the nature of the interaction. E. BV173/E255K cells were treated with BI2536 (2.5 nM) � vorinostat (0.75�M) F. Primary human CML CD34+ samples were isolated as described in Methods and resuspended in medium containing 10% FCS at a cell density of 0.75 x 106/ml cells. Cells were then treated with BI2536 (5.0 nM) � vorinostat (1.0 �M) G. BaF/3 cells expressing wild-type (WT) or mutant forms of BCR/ABL (e.g., E255K, M351T, T315I) were treated with BI2536 (2.0 - 4.0 nM) � vorinostat (0.5-1.25 �M) for 48 hr. For A-G: At the end of drug exposure, the percentage of apoptotic cells was monitored by 7AAD staining as described in Methods. Values represent the means � S.D. for three separate experiments. For all studies, values represent the means for 3 experiments performed in triplicate � S.D.
Supplementary Figure 2 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Authors: Fabre Claire , Mimura Naoya , Bobb Kathryn , Kong Sun-Young , Gorgun Güllü , Cirstea Diana , Hu Yiguo , Minami Jiro , Ohguchi Hiroto , Zhang Jie , Meshulam Jeffrey , Carrasco Ruben D. , Tai Yu-Tzu , Richardson Paul G. , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

PDF file, 50K, Western-Blot IκBα and P-IκBα of MM.1S cells treated with PBS-1086.
Supplementary Figure Legends from U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
Authors: Morgan-Linnell Sonia K. , Stewart David J. , Kurzrock Razelle
Published: April 2023

PDF - 48K, Legends for Supplementary Figures.
Supplementary Figure 2 from U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
Authors: Morgan-Linnell Sonia K. , Stewart David J. , Kurzrock Razelle
Published: April 2023

PDF - 131K, The total number of inspections between 1990-1999 and 2000-2009.
Supplementary Figure Legend from Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans
Authors: Chandran Smita S. , Paria Biman C. , Srivastava Abhishek K. , Rothermel Luke D. , Stephens Daniel J. , Dudley Mark E. , Somerville Robert , Wunderlich John R. , Sherry Richard M. , Yang James C. , Rosenberg Steven A. , Kammula Udai S.
Published: April 2023

Supplementary Figure Legend. Weak and insufficient tumor responses after MDA specific CD8+ T cell clone infusion
Supplementary Figure S5 from miR-204-5p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB22A
Authors: Yin Yuan , Zhang Binbin , Wang Weili , Fei Bojian , Quan Chao , Zhang Jiwei , Song Mingxu , Bian Zehua , Wang Qifeng , Ni Shujuan , Hu Yaling , Mao Yong , Zhou Leyuan , Wang Yugang , Yu Jian , Du Xiang , Hua Dong , Huang Zhaohui
Published: April 2023

Figure S5. The ectopic expression or knockdown of RAB22A in CRC cells. A,The most effective siRNA (siRNA-1) was selected out for further investigation. B, the protein levels of RAB22A were determined by western blotting in LoVo and HCT116 cells transfected with miR-204-5p mimic, RAB22A, siRAB22A or control. Beta-actin served as an internal control.
Figure-S5 from AMACR Amplification in Myxofibrosarcomas: A Mechanism of Overexpression That Promotes Cell Proliferation with Therapeutic Relevance
Authors: Li Chien-Feng , Fang Fu-Min , Lan Jui , Wang Jun-Wen , Kung Hsing-Jien , Chen Li-Tzong , Chen Tzu-Ju , Li Shau-Hsuan , Wang Yu-Hui , Tai Hui-Chun , Yu Shih-Chen , Huang Hsuan-Ying
Published: April 2023

Figure-S5 The associations of AMACR expression with cyclin D1, cyclin T2, and Ki-67 levels in myxofibrosarcoma tissues. In contrast to the primary myxofibrosarcoma specimens with a lower level of AMACR immunoexpression (left column), those with AMACR overexpression (right column) significantly increases expression of cyclin D1, cyclin T2, and Ki-67.
Supplementary Figure S1 from miR-204-5p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB22A
Authors: Yin Yuan , Zhang Binbin , Wang Weili , Fei Bojian , Quan Chao , Zhang Jiwei , Song Mingxu , Bian Zehua , Wang Qifeng , Ni Shujuan , Hu Yaling , Mao Yong , Zhou Leyuan , Wang Yugang , Yu Jian , Du Xiang , Hua Dong , Huang Zhaohui
Published: April 2023

Figure S1. The promoter CpG island of TRPM3/miR-204 is hypermethylation in CRC cells. A, Target sequences in the promote CpG islands of miR-638 gene used for the DNA methylation analysis. The underlined sequences are regions corresponding to the primers of bisulfite-sequencing PCR (BSP) used. B, Schematic representation of the methylation status of the CpG island (including 42 CpG sites) in the TRPM3 promoter as detected in the indicated CRC cell lines. Circles mark different CpG sites in the analyzed sequence. C, The relative mRNA levels of TRPM3 in CRC cell lines. Normal, a pooled sample of noncancerous tissues (NCTs). D, The relative expression of miR-204-5p in CRC cell lines. E, The TRPM3 mRNA levels in CRC cell lines were positively correlated with those of miR-204-5p. F, Quantitative analysis of miR-204-5p expression in CRC cells treated with DNA methyltransferase inhibitor (5-aza-dC). Following treatment of HCT116 and LoVo cells with 5-aza-dC for 72 hours, the miR-204-5p expression in the treated CRC cells was significantly increased compared with untreated control cells (***P < 0.001).
Figure-S2 from AMACR Amplification in Myxofibrosarcomas: A Mechanism of Overexpression That Promotes Cell Proliferation with Therapeutic Relevance
Authors: Li Chien-Feng , Fang Fu-Min , Lan Jui , Wang Jun-Wen , Kung Hsing-Jien , Chen Li-Tzong , Chen Tzu-Ju , Li Shau-Hsuan , Wang Yu-Hui , Tai Hui-Chun , Yu Shih-Chen , Huang Hsuan-Ying
Published: April 2023

Figure-S2 Apoptosis not induced in AMACR-knockdown myxofibrosarcoma cells. In both NMFH-1 (upper) and NMFH-2 (lower) cell lines, the cell percentages in the early and late stages of apoptosis analyzed by annexin V//propodium iodine staining are not significantly different between shLacZ controls and shAMACR-treated cells in three independent assays.
Supplemental Figure and Table Legends from RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma
Authors: Mi Shijun , Lin Mingyan , Brouwer-Visser Jurriaan , Heim Jennifer , Smotkin David , Hebert Tiffany , Gunter Marc J. , Goldberg Gary L. , Zheng Deyou , Huang Gloria S.
Published: April 2023

Supplemental Figure and Table Legends
Suppl Table S4 from RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma
Authors: Mi Shijun , Lin Mingyan , Brouwer-Visser Jurriaan , Heim Jennifer , Smotkin David , Hebert Tiffany , Gunter Marc J. , Goldberg Gary L. , Zheng Deyou , Huang Gloria S.
Published: April 2023

Table S4. Short Tandem Repeat Profiling of Primary Cell Line DNA and Patient Tumor Tissue DNA.
Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
Authors: Haluska Paul , Menefee Michael , Plimack Elizabeth R. , Rosenberg Jonathan , Northfelt Donald , LaVallee Theresa , Shi Li , Yu Xiang-Qing , Burke Patricia , Huang Jaiqi , Viner Jaye , McDevitt Jennifer , LoRusso Patricia
Published: April 2023

Supplementary Methods
Supplementary Figure 7 from Ectopic Expression of Cancer–Testis Antigens in Cutaneous T-cell Lymphoma Patients
Authors: Litvinov Ivan V. , Cordeiro Brendan , Huang Yuanshen , Zargham Hanieh , Pehr Kevin , Doré Marc-André , Gilbert Martin , Zhou Youwen , Kupper Thomas S. , Sasseville Denis
Published: April 2023

PDF file - 66KB, Expression of cTAGE1 and GTSF1 in PBMCs isolated from S�zary Syndrome patients or patients with Benign Inflammatory Dermatoses (BID).
Supplementary Table S3A from Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
Authors: Somlo George , Atzori Francesco , Strauss Lewis C. , Geese William J. , Specht Jennifer M. , Gradishar William J. , Rybicki Alissa , Sy Oumar , Vahdat Linda T. , Cortes Javier
Published: April 2023

PDF file - 27 KB, Table S3A: Biomarker values in patients treated with dasatinib and capecitabine
Supplementary Figure S2 from Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
Authors: Somlo George , Atzori Francesco , Strauss Lewis C. , Geese William J. , Specht Jennifer M. , Gradishar William J. , Rybicki Alissa , Sy Oumar , Vahdat Linda T. , Cortes Javier
Published: April 2023

PDF file - 103 KB, Figure S2A. Progression-free survival (PFS) for all patients treated on study (Kaplan- Meier estimates) Figure S2B. Progression-free survival (PFS) for patients treated at the MTD (DL3a) on study (Kaplan-Meier estimates) Figure S2C. Progression-free survival (PFS) for patients with hormone-receptor positive tumors treated on study (Kaplan-Meier estimates)
Supplementary Tables from LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
Authors: Liu Ling , Zeng Wei , Wortinger Mark A. , Yan S. Betty , Cornwell Paul , Peek Victoria L. , Stephens Jennifer R. , Tetreault Jonathan W. , Xia Jinqi , Manro Jason R. , Credille Kelly M. , Ballard Darryl W. , Brown-Augsburger Patricia , Wacheck Volker , Chow Chi-Kin , Huang Lihua , Wang Yong , Denning Irene , Davies Julian , Tang Ying , Vaillancourt Peter , Lu Jirong
Published: April 2023

Supplementary Tables. Supplementary Table S1. Summary of cell lines used. Supplementary Table S2. Summary of Repeat-Dose Toxicity Study with LY2875358
Figure S2 from ABO Blood Group IgM Isoagglutinins Interact with Tumor-Associated O-Glycan Structures in Pancreatic Cancer
Authors: Hofmann Bianca T. , Stehr Anne , Dohrmann Thorsten , Güngör Cenap , Herich Lena , Hiller Jens , Harder Sönke , Ewald Florian , Gebauer Florian , Tachezy Michael , Precht Clarissa , Izbicki Jakob R. , Bockhorn Maximilian , Wagener Christoph , Wolters-Eisfeld Gerrit
Published: April 2023

Supplemental Figure S2 A-D: Isoagglutinin titers of blood group O, A and B. Isoagglutinin titers were determined for blood group O, A and B with absolute numbers of PDAC sera or healthy control sera. A: Blood group O PDAC sera showed a median anti-A titer of 1:16 (range 15 - 17) compared to 1:64 in the control (range 48 - 80). B: Blood group O PDAC sera showed a median anti-B titer of 1:8 (range 6 - 10) compared to control with a titer of 1:64 (range 32 - 96). C: Blood group A PDAC sera showed a median anti-B titer of 1:8 (range 7 - 9) compared to 1:64 in the control (range 48 - 80). D: Blood group B PDAC sera showed a median anti-A titer of 1:4 (range 2 - 6) compared to 1:64 in the control (range 56 - 72).
Figure S1 from ABO Blood Group IgM Isoagglutinins Interact with Tumor-Associated O-Glycan Structures in Pancreatic Cancer
Authors: Hofmann Bianca T. , Stehr Anne , Dohrmann Thorsten , Güngör Cenap , Herich Lena , Hiller Jens , Harder Sönke , Ewald Florian , Gebauer Florian , Tachezy Michael , Precht Clarissa , Izbicki Jakob R. , Bockhorn Maximilian , Wagener Christoph , Wolters-Eisfeld Gerrit
Published: April 2023

Supplemental Figure S1: Relative Survival of PDAC patients with different blood groups. Kaplan Meier survival plot shows relative survival of PDAC patients in blood group O (blue), blood group A (green), blood group B (yellow) and blood group AB (purple). No significant statistical association was observed.
Supplementary Table 1 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Authors: Pal Sumanta , Azad Arun , Bhatia Shailender , Drabkin Harry , Costello Brian , Sarantopoulos John , Kanesvaran Ravindran , Lauer Richard , Starodub Alexander , Hauke Ralph , Sweeney Christopher J. , Hahn Noah M. , Sonpavde Guru , Richey Stephen , Breen Timothy , Kremmidiotis Gabriel , Leske Annabell , Doolin Elizabeth , Bibby David C. , Simpson Jeremy , Iglesias Jose , Hutson Thomas
Published: April 2023

Supplementary Table 1. List of 40 exploratory plasma biomarkers investigated.
Supplementary Table 2 from T-Cell Levels Are Prognostic in Mantle Cell Lymphoma
Authors: Nygren Lina , Wasik Agata M. , Baumgartner-Wennerholm Stefanie , Jeppsson-Ahlberg Åsa , Klimkowska Monika , Andersson Patrik , Buhrkuhl Daren , Christensson Birger , Kimby Eva , Wahlin Björn E. , Sander Birgitta
Published: April 2023

Supplementary Table 2. T cell levels in diagnostic MCL lymph nodes expressed as median and range of percentage of cells in mononuclear gate.
Supplementary Table 1 from T-Cell Levels Are Prognostic in Mantle Cell Lymphoma
Authors: Nygren Lina , Wasik Agata M. , Baumgartner-Wennerholm Stefanie , Jeppsson-Ahlberg Åsa , Klimkowska Monika , Andersson Patrik , Buhrkuhl Daren , Christensson Birger , Kimby Eva , Wahlin Björn E. , Sander Birgitta
Published: April 2023

Supplementary Table 1. Information regarding the antibody clones used in multiparameter flow cytometry.
Supplementary Figure Legend from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
Authors: Filipazzi Paola , Pilla Lorenzo , Mariani Luigi , Patuzzo Roberto , Castelli Chiara , Camisaschi Chiara , Maurichi Andrea , Cova Agata , Rigamonti Gianluigi , Giardino Felicetta , Di Florio Annabella , Asioli Marco , Frati Paola , Sovena Gloria , Squarcina Paola , Maio Michele , Danielli Riccardo , Chiarion-Sileni Vanna , Villa Antonello , Lombardo Claudia , Tragni Gabrina , Santinami Mario , Parmiani Giorgio , Rivoltini Licia
Published: April 2023

PDF file - 90K
Supplementary Figure 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
Authors: Filipazzi Paola , Pilla Lorenzo , Mariani Luigi , Patuzzo Roberto , Castelli Chiara , Camisaschi Chiara , Maurichi Andrea , Cova Agata , Rigamonti Gianluigi , Giardino Felicetta , Di Florio Annabella , Asioli Marco , Frati Paola , Sovena Gloria , Squarcina Paola , Maio Michele , Danielli Riccardo , Chiarion-Sileni Vanna , Villa Antonello , Lombardo Claudia , Tragni Gabrina , Santinami Mario , Parmiani Giorgio , Rivoltini Licia
Published: April 2023

PDF file - 66K, Correlations between multiple immunological parameters and DFS
Supplementary Methods from Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis
Authors: Dal Molin Marco , Zhang Ming , de Wilde Roeland F. , Ottenhof Niki A. , Rezaee Neda , Wolfgang Christopher L. , Blackford Amanda , Vogelstein Bert , Kinzler Kenneth W. , Papadopoulos Nickolas , Hruban Ralph H. , Maitra Anirban , Wood Laura D.
Published: April 2023

Supplementary Methods. This document provides detailed methods for library preparation, sequencing, and SafeSeq.
Supplemental methods, Supplemental tables S1-S3, Supplemental Figure S1-S8 Legends from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients
Authors: Guo Yuna , Kenney S. Ray , Cook Linda , Adams Sarah F. , Rutledge Teresa , Romero Elsa , Oprea Tudor I. , Sklar Larry A. , Bedrick Edward , Wiggins Charles L. , Kang Huining , Lomo Lesley , Muller Carolyn Y. , Wandinger-Ness Angela , Hudson Laurie G.
Published: April 2023

Supplemental methods, Supplemental tables S1-S3, Supplemental Figure S1-S8 Legends. Supplemental methods for IHC of patient TMA, qPCR of patient cDNA, HPLC protocol, and GTPase activity of patient cells. Figure legends for supplemental figures S1-S8 are included. Supplemental table S1 - Patient Characteristics for IHC Microarrays OV1005 and OV8010. Supplemental table S2 - Patient Characteristics for cDNA Microarray. Supplemental table S3 - Ketorolac enantiomer concentration in serum or peritoneal fluids
Supplementary Figure 2 from A Promyelocytic Leukemia Protein–Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma
Authors: Dvorkina Maria , Nieddu Valentina , Chakelam Shalini , Pezzolo Annalisa , Cantilena Sandra , Leite Ana Paula , Chayka Olesya , Regad Tarik , Pistorio Angela , Sementa Angela Rita , Virasami Alex , Barton Jack , Montano Ximena , Lechertier Tanguy , Brindle Nicola , Morgenstern Daniel , Lebras Morgane , Burns Alan J. , Saunders Nigel J. , Hodivala-Dilke Kairbaan , Bagella Luigi , De The Hugues , Anderson John , Sebire Neil , Pistoia Vito , Sala Arturo , Salomoni Paolo
Published: April 2023

PML and HIF1a expression
Supplemental Materials from Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR
Authors: Watanabe Masaru , Kawaguchi Tomoya , Isa Shun-ichi , Ando Masahiko , Tamiya Akihiro , Kubo Akihito , Saka Hideo , Takeo Sadanori , Adachi Hirofumi , Tagawa Tsutomu , Kakegawa Seiichi , Yamashita Motohiro , Kataoka Kazuhiko , Ichinose Yukito , Takeuchi Yukiyasu , Sakamoto Kazuhiro , Matsumura Akihide , Koh Yasuhiro
Published: April 2023

Supplementary Materials and Methods, Reference and Supplementary Figure Legends
Supplementary Table 3 from Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome
Authors: Caliò Anna , Zamò Alberto , Ponzoni Maurilio , Zanolin Maria Elisabetta , Ferreri Andrés J.M. , Pedron Serena , Montagna Licia , Parolini Claudia , Fraifeld Vadim E. , Wolfson Marina , Yanai Hagai , Pizzolo Giovanni , Doglioni Claudio , Vinante Fabrizio , Chilosi Marco
Published: April 2023

MARQ analysis for common gene expression signatures of Hodgkin's lymphoma.
Supplemental Table 6 from First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Authors: Shapiro Geoffrey I. , Bell-McGuinn Katherine M. , Molina Julian R. , Bendell Johanna , Spicer James , Kwak Eunice L. , Pandya Susan S. , Millham Robert , Borzillo Gary , Pierce Kristen J. , Han Lixin , Houk Brett E. , Gallo Jorge D. , Alsina Maria , Braña Irene , Tabernero Josep
Published: April 2023

Supplemental Table 6. Changes observed in metabolic biomarker levels following treatment with PF-05212384
Supplementary Figure S1 from Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer
Authors: Koido Shigeo , Homma Sadamu , Okamoto Masato , Takakura Kazuki , Mori Masako , Yoshizaki Shinji , Tsukinaga Shintaro , Odahara Shunichi , Koyama Seita , Imazu Hiroo , Uchiyama Kan , Kajihara Mikio , Arakawa Hiroshi , Misawa Takeyuki , Toyama Yoichi , Yanagisawa Satoru , Ikegami Masahiro , Kan Shin , Hayashi Kazumi , Komita Hideo , Kamata Yuko , Ito Masaki , Ishidao Takefumi , Yusa Sei-ichi , Shimodaira Shigetaka , Gong Jianlin , Sugiyama Haruo , Ohkusa Toshifumi , Tajiri Hisao
Published: April 2023

Study profile.
Supplemental Table 3 from First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Authors: Shapiro Geoffrey I. , Bell-McGuinn Katherine M. , Molina Julian R. , Bendell Johanna , Spicer James , Kwak Eunice L. , Pandya Susan S. , Millham Robert , Borzillo Gary , Pierce Kristen J. , Han Lixin , Houk Brett E. , Gallo Jorge D. , Alsina Maria , Braña Irene , Tabernero Josep
Published: April 2023

Supplemental Table 3. Cycle 1 results of the pharmacokinetic analysis of PF-05212384 administered at the maximum tolerated dose
Supplementary Tables 8 - 15 from Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Authors: Cui Yunfeng , Brosnan Jacqueline A. , Blackford Amanda L. , Sur Surojit , Hruban Ralph H. , Kinzler Kenneth W. , Vogelstein Bert , Maitra Anirban , Diaz Luis A. , Iacobuzio-Donahue Christine A. , Eshleman James R.
Published: April 2023

PDF file, 127K, S8 IC50s of DPC4/SMAD4 isogenic cells tested with Cisplatin, Irinotecan and Gemcitabine; S9 Correlation analysis between IC50s of Cisplatin, Irinotecan and Gemcitabine and TGFB pathway activity of DPC4 isogenic cells; S10 Genes whose expression levels were correlated with chemosensitivity in pancreatic cancer cell lines; S11 Combination indices (CI) for csplatin+irinotecan combination in DPC4 isogenic cell lines; S12 IC50s of TP53 isogenic colon cancer cell lines tested with Parp1 inhibitor and Triptolide; S13 Comparisons of gene mutation statuses of cell lines having IC50<200nM with those having IC50>10000nM for Parp1 inhibitor; S14 Genes with significantly different gene expression in cell cycle and DNA damage pathway and other DNA damage repair genes without significant difference between TP53 defective PC cell lines having IC50<200nM and those having IC50>10000nM for Parp1 inhibitor; S15 P16/CDKN2A deleted PC cells rank ordered by their sensitivity to gemcitabine and MMC investigated for association with CDKN2B, DMRTA1, MTAP and TUSC1 in pancreatic cancer cells.
Supplementary Tables 1 - 7 from Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Authors: Cui Yunfeng , Brosnan Jacqueline A. , Blackford Amanda L. , Sur Surojit , Hruban Ralph H. , Kinzler Kenneth W. , Vogelstein Bert , Maitra Anirban , Diaz Luis A. , Iacobuzio-Donahue Christine A. , Eshleman James R.
Published: April 2023

PDF file, 72K, S1 Characteristics of human pancreatic cancer cell lines used in this study; S2 Characteristics of human DPC4/SMAD4 isogenic pancreatic cancer cell lines; S3 Characteristics of human TP53 isogenic colon cancer cell lines; S4 IC50 values (nM) of Gemcitabine, Triptolide, Docetaxel, MMC, Cisplatin, Irinotecan, Parp1 inhibitor and Artemisinin for human PC cell lines; S5 IC50 values (nM) of Gemcitabine, Triptolide, Docetaxel, MMC, Cisplatin, Irinotecan, Parp1 inhibitor and Artemisinin for human pancreatic cancer cell lines; S6 Correlation analysis between chemosensitivity and somatic mutations alone, homozygous deletion alone or both in pancreatic cancer cells identified in the discovery and prevalence screen arranged by drugs.
Supplementary Figures 1 - 5 from Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Authors: Cui Yunfeng , Brosnan Jacqueline A. , Blackford Amanda L. , Sur Surojit , Hruban Ralph H. , Kinzler Kenneth W. , Vogelstein Bert , Maitra Anirban , Diaz Luis A. , Iacobuzio-Donahue Christine A. , Eshleman James R.
Published: April 2023

PDF file, 1588K, S1: Correlations of drug response to DPC4 genotype; S2: Correlations of drug response to P16 genotype; S3: Reponses of isogenic cancer cell lines to anticancer drugs; S4: Gene expression profiles correlated with chemotherapeutic response; S5: Gene expression profiles correlated with DPC4/SMAD4.md, TP53.md and P16/CDKN2A.md.
Supplementary tables S1-S7 from Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials
Authors: Clavarezza Matteo , Puntoni Matteo , Gennari Alessandra , Paleari Laura , Provinciali Nicoletta , D'Amico Mauro , DeCensi Andrea
Published: April 2023

Supplementary Table S1. Results of the summary evaluation on the risk of bias assessment, using the domain-based evaluation of the Cochrane risk of bias tool: low, unclear, and high risk of bias are the 3 possible judgments for each item considered of each of the study assessed. Supplementary Table S2. Detailed results of the risk of bias assessment on the NEOALTTO study (ref. 39). Supplementary Table S3. Detailed results of the risk of bias assessment on the CALGB 40601 study (ref. 40). Supplementary Table S4. Detailed results of the risk of bias assessment on the NSABP B-41 study (ref. 41). Supplementary Table S5. Detailed results of the risk of bias assessment on the EORTC 10054 study (ref. 42). Supplementary Table S6. Detailed results of the risk of bias assessment on the TRIO-US B07 study (ref. 43). Supplementary Table S7. Detailed results of the risk of bias assessment on the CHERLOB study (ref. 44).
Supplementary Table 2 from LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma
Authors: Yeung Jacky T. , Hamilton Ronald L. , Ohnishi Koji , Ikeura Maki , Potter Douglas M. , Nikiforova Marina N. , Ferrone Soldano , Jakacki Regina I. , Pollack Ian F. , Okada Hideho
Published: April 2023

PDF file - 96K, Summary of specificity of anti-HLA Class I antibodies.
Supplementary Tables 1 - 6 from Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry
Authors: Mulligan Anna Marie , Raitman Irene , Feeley Linda , Pinnaduwage Dushanthi , Nguyen Linh T. , O'Malley Frances P. , Ohashi Pamela S. , Andrulis Irene L.
Published: April 2023

PDF file - 104K, Table S1. Summary of antibodies and conditions of use Table S2. Pathologic Characteristics of the Breast Tumors Table S3. Association between CXCL10 and CD4 and CD8 peritumoral expression Table S4. (A) Association between FOXP3 and Molecular Biomarkers Table S4. (B) Association between T-BET and Molecular Biomarkers Table S5. (A) Association of FOXP3 and subgroups Table S5. (B) Association of T-BET and subgroups Table S6. (A) Association between FOXP3 and Clinicopathologic parameters Table S6. (B) Association between T-BET and Clinicopathologic parameters
Supplementary Figure 3 from Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation
Authors: Hedayati Mohammad , Haffner Michael C. , Coulter Jonathan B. , Raval Raju R. , Zhang Yonggang , Zhou Haoming , Mian Omar , Knight Emma J. , Razavi Nina , Dalrymple Susan , Isaacs John T. , Santos Aileen , Hales Russell , Nelson William G. , Yegnasubramanian Srinivasan , DeWeese Theodore L.
Published: April 2023

Clonogenic survival of PC3 cells following IR and DHT treatments. Clonogenic survival fraction is shown for AR negative PC3 cells exposed to vehicle control, 100 nM DHT, 4 Gy of IR or the combination of both. NS, not significant.
Supplementary Figure from Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805
Authors: Haas Naomi B. , Manola Judith , Ky Bonnie , Flaherty Keith T. , Uzzo Robert G. , Kane Christopher J. , Jewett Michael , Wood Lori , Wood Christopher G. , Atkins Michael B. , Dutcher Janice J. , Wilding George , DiPaola Robert S.
Published: April 2023

Supplementary Figure: Consort diagram of patients participating in cardiac sub study
Supplementary Figure 1 from Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation
Authors: Hedayati Mohammad , Haffner Michael C. , Coulter Jonathan B. , Raval Raju R. , Zhang Yonggang , Zhou Haoming , Mian Omar , Knight Emma J. , Razavi Nina , Dalrymple Susan , Isaacs John T. , Santos Aileen , Hales Russell , Nelson William G. , Yegnasubramanian Srinivasan , DeWeese Theodore L.
Published: April 2023

DNA repair genes following androgen stimulation. Androgen-deprived LNCaP cells were exposed to vehicle or 100nM DHT for the indicated times and mRNA of classical AR-regulated genes (A) or DNA repair-related genes (B) were measured using qRT-PCR. mRNA levels are expressed relative to GAPDH expression and normalized to levels in androgen-deprived conditions.
Supplementary Table 1 from A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
Authors: Ferrucci Arianna , Moschetta Michele , Frassanito Maria Antonia , Berardi Simona , Catacchio Ivana , Ria Roberto , Racanelli Vito , Caivano Antonella , Solimando Antonio Giovanni , Vergara Daniele , Maffia Michele , Latorre Dominga , Rizzello Antonia , Zito Alfredo , Ditonno Paolo , Maiorano Eugenio , Ribatti Domenico , Vacca Angelo
Published: April 2023

Supplementary Table 1. Real time RT-PCR primers.
Supplementary Legends from A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
Authors: Ferrucci Arianna , Moschetta Michele , Frassanito Maria Antonia , Berardi Simona , Catacchio Ivana , Ria Roberto , Racanelli Vito , Caivano Antonella , Solimando Antonio Giovanni , Vergara Daniele , Maffia Michele , Latorre Dominga , Rizzello Antonia , Zito Alfredo , Ditonno Paolo , Maiorano Eugenio , Ribatti Domenico , Vacca Angelo
Published: April 2023

Supplementary Legends
Supplementary Figure S3 from A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
Authors: Ferrucci Arianna , Moschetta Michele , Frassanito Maria Antonia , Berardi Simona , Catacchio Ivana , Ria Roberto , Racanelli Vito , Caivano Antonella , Solimando Antonio Giovanni , Vergara Daniele , Maffia Michele , Latorre Dominga , Rizzello Antonia , Zito Alfredo , Ditonno Paolo , Maiorano Eugenio , Ribatti Domenico , Vacca Angelo
Published: April 2023

Supplementary Figure S3. Proteome analysis of MMECs upon treatment with SU11274 plus bortezomib or lenalidomide.
Supplementary figure legend from Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Authors: Giuliano Mario , Hu Huizhong , Wang Yen-Chao , Fu Xiaoyong , Nardone Agostina , Herrera Sabrina , Mao Sufeng , Contreras Alejandro , Gutierrez Carolina , Wang Tao , Hilsenbeck Susan G. , De Angelis Carmine , Wang Nicholas J. , Heiser Laura M. , Gray Joe W. , Lopez-Tarruella Sara , Pavlick Anne C. , Trivedi Meghana V. , Chamness Gary C. , Chang Jenny C. , Osborne C. Kent , Rimawi Mothaffar F. , Schiff Rachel
Published: April 2023

Supplementary figure legend. Legend of supplementary Figure 1 and 2
Supplementary Figure 3 from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Authors: Small Eric J. , Lance Raymond S. , Gardner Thomas A. , Karsh Lawrence I. , Fong Lawrence , McCoy Candice , DeVries Todd , Sheikh Nadeem A. , GuhaThakurta Debraj , Chang Nancy , Redfern Charles H. , Shore Neal D.
Published: April 2023

Supplementary Figure 3. CONSORT diagram with patient disposition.
Supplementary Figure 2 from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Authors: Small Eric J. , Lance Raymond S. , Gardner Thomas A. , Karsh Lawrence I. , Fong Lawrence , McCoy Candice , DeVries Todd , Sheikh Nadeem A. , GuhaThakurta Debraj , Chang Nancy , Redfern Charles H. , Shore Neal D.
Published: April 2023

Supplementary Figure 2. Schematic showing how sipuleucel-T is designed to activate a patient's immune system by ex vivo cellular activation during manufacture and subsequent in vivo immune response.
Supplementary Table 9 from A MicroRNA Cluster at 14q32 Drives Aggressive Lung Adenocarcinoma
Authors: Nadal Ernest , Zhong Jinjie , Lin Jules , Reddy Rishindra M. , Ramnath Nithya , Orringer Mark B. , Chang Andrew C. , Beer David G. , Chen Guoan
Published: April 2023

XLSX file - 19KB, Table S9- List of studies that identified prognostic miRs in lung cancer by miR profiling.
Supplementary Figure 1 from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Authors: Small Eric J. , Lance Raymond S. , Gardner Thomas A. , Karsh Lawrence I. , Fong Lawrence , McCoy Candice , DeVries Todd , Sheikh Nadeem A. , GuhaThakurta Debraj , Chang Nancy , Redfern Charles H. , Shore Neal D.
Published: April 2023

Supplementary Figure 1. Schematic of the STAMP trial design.
Supplementary Figure 6 from Chloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer
Authors: Cook Katherine L. , Wärri Anni , Soto-Pantoja David R. , Clarke Pamela AG. , Cruz M. Idalia , Zwart Alan , Clarke Robert
Published: April 2023

Circulating mouse cytokine and chemokine involvement. A. Interferon-ÃƒÆ’Ã…Â½Ãƒâ€šÃ‚Â³ and TNFÃƒÆ’Ã…Â½{plus minus} were measured by ELISA in plasma from mice treated with control, CQ, ICI, ICI+CQ, TAM, and TAM+CQ. n=3-6
S3: Evolution of MDM2 and TP53 status over time of 5 patients affected by MDM2-amplified GBM. from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Authors: Verreault Maite , Schmitt Charlotte , Goldwirt Lauriane , Pelton Kristine , Haidar Samer , Levasseur Camille , Guehennec Jeremy , Knoff David , Labussière Marianne , Marie Yannick , Ligon Azra H. , Mokhtari Karima , Hoang-Xuan Khê , Sanson Marc , Alexander Brian M. , Wen Patrick Y. , Delattre Jean-Yves , Ligon Keith L. , Idbaih Ahmed
Published: April 2023

S3: Evolution of MDM2 and TP53 status over time of 5 patients affected by MDM2-amplified GBM.
Supplementary Figure 2 from Chloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer
Authors: Cook Katherine L. , Wärri Anni , Soto-Pantoja David R. , Clarke Pamela AG. , Cruz M. Idalia , Zwart Alan , Clarke Robert
Published: April 2023

Effect of antiestrogen therapy in vivo. A. LCC9 control, TAM, and ICI treated tumors sections were stained with an antibody against ERÃƒÆ’Ã…Â½Ãƒâ€šÃ‚Â± or the progesterone receptor to show antiestrogen effectiveness.
Supplementary Figures 1-3, Supplementary Tables 1-2, Supplementary References from Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Authors: Baselga José , Lewis Phillips Gail D. , Verma Sunil , Ro Jungsil , Huober Jens , Guardino Alice E. , Samant Meghna K. , Olsen Steve , de Haas Sanne L. , Pegram Mark D.
Published: April 2023

Supplementary Fig 1. Overall survival by HER2 mRNA percentile Supplementary Fig 2. Patient disposition and biomarker availability in the EMILIA trial. Supplementary Fig 3. Potential mechanism by which T-DM1 may bypass a common resistance pathway in HER2-positive cancer cells Supplementary Table 1. REMARK2 Checklist. Supplementary Table 2. Selected Patient Demographic and Baseline Characteristics by Treatment Arm in Evaluable and Nonevaluable Patients.
Supplemental Table 1 from Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma
Authors: Gustafson Michael P. , Lin Yi , Bleeker Jonathan S. , Warad Deepti , Tollefson Matthew K. , Crispen Paul L. , Bulur Peggy A. , Harrington Susan M. , Laborde Rebecca R. , Gastineau Dennis A. , Leibovich Bradley C. , Cheville John C. , Kwon Eugene D. , Dietz Allan B.
Published: April 2023

Supplemental Table 1. CD14 expression for 375 ccRCC patients
Supplementary Figures 1 - 3 from RNAi Screen Identifies a Synthetic Lethal Interaction between PIM1 Overexpression and PLK1 Inhibition
Authors: van der Meer Riet , Yong Song Ha , Park Seong-Hoon , Abdulkadir Sarki A. , Roh Meejeon
Published: April 2023

PDF file - 331KB, Figure S1. PLK1 immumnoblotting for endogenous and synchronized cells. Figure S2. Immunostaining of LNCaP xenografts. Figure S3. Myc immunoblotting after BI 2536 treatment.
Supplement from Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer
Authors: Heid Irina , Steiger Katja , Trajkovic-Arsic Marija , Settles Marcus , Eßwein Manuela R. , Erkan Mert , Kleeff Jörg , Jäger Carsten , Friess Helmut , Haller Bernhard , Steingötter Andreas , Schmid Roland M. , Schwaiger Markus , Rummeny Ernst J. , Esposito Irene , Siveke Jens T. , Braren Rickmer F.
Published: April 2023

Supplementary Figure 1. Summary and survival of murine cohort used in the study. Supplementary Figure 2 Consort diagram of the patient distribution of surgical subcohort 1. Supplementary Figure 3. Consort diagram of the patient distribution of surgical subcohort 2. Supplementary Figure 4. Consort diagram of the patient distribution of surgical subcohort 3. Supplementary Figure 5. Schematic of relative tumor cell and stroma contribution in PDAChigh Supplementary Table 1. Statistics of the patients used in surgical subcohort 1. Supplementary Table 2. Statistics of the patients used in surgical subcohort 2. Supplementary Table 3. Statistics of the patients used in surgical subcohort 3. Supplementary Table 4. Results of a multivariable Cox regression model fit to the data of subcohort 2 that assess whether PDAC is associated with overall survival after adjustment for common predictors. Supplementary Table 5. The permutation test analysis revealing association between overall survival and lowest ADC stratified by each of the relevant categorical variables. Data used for analysis are derived from surgical subcohort 3.
Supplemental Figure 1 from Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma
Authors: Gustafson Michael P. , Lin Yi , Bleeker Jonathan S. , Warad Deepti , Tollefson Matthew K. , Crispen Paul L. , Bulur Peggy A. , Harrington Susan M. , Laborde Rebecca R. , Gastineau Dennis A. , Leibovich Bradley C. , Cheville John C. , Kwon Eugene D. , Dietz Allan B.
Published: April 2023

Supplemental Figure 1. Principal component analysis of ten immunophenotypes measured in healthy volunteers and renal cell carcinoma patients.
Legend for Supplemental Figure 2legend from Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma
Authors: Gustafson Michael P. , Lin Yi , Bleeker Jonathan S. , Warad Deepti , Tollefson Matthew K. , Crispen Paul L. , Bulur Peggy A. , Harrington Susan M. , Laborde Rebecca R. , Gastineau Dennis A. , Leibovich Bradley C. , Cheville John C. , Kwon Eugene D. , Dietz Allan B.
Published: April 2023

Legend for Supplemental Figure 2
Supplementary Figure 2 from Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Authors: Wainwright Derek A. , Chang Alan L. , Dey Mahua , Balyasnikova Irina V. , Kim Chung Kwon , Tobias Alex , Cheng Yu , Kim Julius W. , Qiao Jian , Zhang Lingjiao , Han Yu , Lesniak Maciej S.
Published: April 2023

PDF file - 2088KB, Supplementary Figure 2. Therapeutic blockade at 2 weeks post-intracranial injection (wpic.) against CTLA-4, PD-L1 and IDO selectively changes the T cell phenotype in established brain tumors.
Supplementary Table 3 from Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression
Authors: Lopez Sandra M. , Agoulnik Alexander I. , Zhang Manqi , Peterson Leif E. , Suarez Egla , Gandarillas Gregory A. , Frolov Anna , Li Rile , Rajapakshe Kimal , Coarfa Christian , Ittmann Michael M. , Weigel Nancy L. , Agoulnik Irina U.
Published: April 2023

AR signature in LNCaP cells
Supplementary Figure 2 from Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer
Authors: Chan Alison , Prassas Ioannis , Dimitromanolakis Apostolos , Brand Randall E. , Serra Stefano , Diamandis Eleftherios P. , Blasutig Ivan M.
Published: April 2023

Supplementary Figure 2. Diagnostic performances of CA19.9, CA125, LAMC2, AGR2, SYCN and REG1B for all PDAC patients versus healthy controls as individual markers. Receiver operator characteristics (ROC) curves for CA19.9, CA125, LAMC2, AGR2, SYCN and REG1B for all patients with pancreatic ductal adenocarcinoma (PDAC) versus all healthy controls as individual markers in the training cohort (A) and validation cohort (B). The area under the curve (AUC) for each marker is provided along with its associated 95% confidence intervals in brackets.
Supplementary Table 1 from Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression
Authors: Lopez Sandra M. , Agoulnik Alexander I. , Zhang Manqi , Peterson Leif E. , Suarez Egla , Gandarillas Gregory A. , Frolov Anna , Li Rile , Rajapakshe Kimal , Coarfa Christian , Ittmann Michael M. , Weigel Nancy L. , Agoulnik Irina U.
Published: April 2023

NCOR1 regulated pathways
Supplementary Figure 1 from Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer
Authors: Chan Alison , Prassas Ioannis , Dimitromanolakis Apostolos , Brand Randall E. , Serra Stefano , Diamandis Eleftherios P. , Blasutig Ivan M.
Published: April 2023

Supplementary Figure 1. Scatter plots of AGR2, SYCN and REG1B in the training and validation cohorts. AGR2 (A,B), REG1B (C,D) and SYCN (E,F) for training and validation cohorts respectively. Black horizontal lines represent the medians. PDAC=pancreatic ductal adenocarcinoma.
Supplementary Figures from Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression
Authors: Lopez Sandra M. , Agoulnik Alexander I. , Zhang Manqi , Peterson Leif E. , Suarez Egla , Gandarillas Gregory A. , Frolov Anna , Li Rile , Rajapakshe Kimal , Coarfa Christian , Ittmann Michael M. , Weigel Nancy L. , Agoulnik Irina U.
Published: April 2023

Supplementary Figure 1 Comparison of NCOR1 and NCOR2 knockdown in LAPC4 and LNCaP cells Supplementary Figure 2 NCOR1 regulates motility of LNCaP cells Supplementary Figure 3 AR signature is present among bicalutamide treated genes in both control and NCOR1 depleted cells Supplementary Figure 4 Comparative levels of UGT2B15 and UGT2B17 mRNA expression in LNCaP and C4-2 cells Supplementary Figure 5 Loss of both UGT2B 15 and UGT2B 17 lead to elevated DHT-dependent PSA expression. Supplementary Figure 6 NCOR1 is required for optimal TARP and CHEK1 expression in LAPC4 cells Supplementary Figure 7 AR is recruited to PSA enhancer and INPP4B promoter after NCOR1 depletion Supplementary Figure 8 Examples of variable NCOR1 staining in normal prostate epithelium, PIN, and prostate cancer on tissue microarray.
Supplemental Material from Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer
Authors: Chan Alison , Prassas Ioannis , Dimitromanolakis Apostolos , Brand Randall E. , Serra Stefano , Diamandis Eleftherios P. , Blasutig Ivan M.
Published: April 2023

Supplemental Material